Omega-3 or Coenzyme Q10: what's the difference

Omega-3 fatty acids and coenzyme Q10 often sit side by side on the “for the heart” shelf, and many people treat them as interchangeable supplements. In reality these are substances of different chemical classes that work in different parts of the cell and have completely different evidence bases. Our editorial team examined exactly what sets them apart.

Two different substances: chemistry and origin

Omega-3s are a family of polyunsaturated fatty acids in which the first double bond sits near the third carbon atom from the methyl end of the chain. The three most important ones for humans are: alpha-linolenic acid (ALA) of plant origin, plus eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, which come mainly from marine fish and algae.

The body can synthesise EPA and DHA from ALA, but in humans this conversion is inefficient, especially for DHA. So from a practical standpoint the “long” omega-3s are considered conditionally essential: their level in tissues depends largely on diet or supplements.

Coenzyme Q10, or ubiquinone, belongs to an entirely different class — it is a fat-soluble quinone compound with a long isoprenoid “tail” of ten units (hence the number 10 in the name). Unlike EPA and DHA, coenzyme Q10 is not essential: the body synthesises it itself in almost all tissues.

Coenzyme Q10 synthesis follows the same mevalonate pathway as cholesterol synthesis. This fact has practical significance: statins, which block the enzyme HMG-CoA reductase, simultaneously lower blood coenzyme Q10 levels. With age, the body's own production of the substance also gradually declines.

So the first key difference is this: omega-3s are structural fats that the body largely obtains from outside, whereas coenzyme Q10 is the body's own metabolite, additional intake of which makes sense only in specific situations.

Where and how they work in the cell

EPA and DHA are incorporated into the phospholipids of cell membranes. Membrane composition determines their fluidity and the functioning of receptors and ion channels. DHA is especially abundant in the retina of the eye, the grey matter of the brain and in sperm cells, which explains its importance for vision and the nervous system.

The second role of omega-3s is a signalling one. EPA gives rise to eicosanoids with lower pro-inflammatory activity than the derivatives of arachidonic acid (omega-6), as well as specialised mediators that resolve inflammation — resolvins, protectins and maresins. In addition, in the liver omega-3s reduce triglyceride synthesis and the formation of very-low-density lipoproteins.

Coenzyme Q10 works mainly in the mitochondria. In the respiratory chain it carries electrons from complexes I and II to complex III, enabling the production of ATP — the cell's main energy “fuel”. It is most abundant in organs with high energy demands: the heart, liver and kidneys.

The reduced form of the coenzyme — ubiquinol — also acts as a fat-soluble antioxidant in membranes and lipoproteins, helping to regenerate vitamin E. So if omega-3s change the cell's “building material” and signals, then Q10 takes part in its energy metabolism and antioxidant defence.

Because of this difference in mechanisms, these substances do not compete with each other and can potentially complement one another. However, “complementary in theory” does not yet mean “clinically beneficial” — that is now a question of evidence.

What has been proven in clinical trials

The strongest evidence for omega-3s is a dose-dependent reduction in blood triglycerides. High doses of EPA and DHA in prescription form are used for hypertriglyceridaemia. In the REDUCE-IT trial, a highly purified ethyl ester of EPA (icosapent ethyl, 4 g per day) in patients with elevated triglycerides on top of statins reduced the rate of major cardiovascular events.

At the same time, for ordinary doses of fish oil in the general population the results are more modest. The large VITAL trial with 1 g of marine omega-3 per day showed no significant reduction in the primary composite cardiovascular endpoint. For athletes there are data on a possible effect on the sensation of muscle soreness and, in older people, on muscle mass and function, but these effects are moderate.

Coenzyme Q10 has the best data in chronic heart failure. In the randomised Q-SYMBIO trial, taking 300 mg per day for two years was accompanied by a lower rate of major cardiovascular events, although the trial was relatively small and needs confirmation.

Another popular area is muscle symptoms in people taking statins. Here the data are contradictory: the meta-analysis by Banach and colleagues (2015) found no convincing benefit of coenzyme Q10 in relieving statin myopathy. As for improving athletic performance in healthy people, there is also no convincing evidence for Q10.

• Omega-3:proven reduction of triglycerides; selective benefit for cardiovascular risk at high doses of EPA; moderate data on recovery.
• Coenzyme Q10:encouraging but limited data in heart failure; ambiguous in statin-related myalgia; weak for endurance.

Safety, interactions and product quality

Both supplements are usually well tolerated. For omega-3s the most common complaints are fishy-tasting burps and stomach discomfort. EFSA concluded that long-term intake of EPA and DHA combined up to 5 g per day raises no safety concerns in adults.

At the same time, large cardiology trials of high-dose omega-3s observed a somewhat higher rate of atrial fibrillation. The meta-analysis by Gencer and colleagues (2021) linked this risk primarily to doses above 1 g per day. People with rhythm disorders and those taking anticoagulants should discuss intake with their doctor.

For coenzyme Q10 the most important interaction is with warfarin: a reduction of its effect has been described, so with this therapy INR monitoring is required. Side effects of Q10 are usually limited to mild digestive upset and, in some people, disturbed sleep when taken in the evening.

Product quality is assessed differently for the two supplements. In fish oil what matters is the concentration of EPA+DHA per capsule (not just “1000 mg of oil”), the degree of oxidation and purification from heavy metals. For Q10 the form (ubiquinone or ubiquinol) and the presence of an oil base matter, because the substance is poorly absorbed without fats.

A side-by-side comparison table

To make the difference clear, we have gathered the main characteristics of the two supplements into a single table. Note: these are general patterns, not individual recommendations.

The table shows the main point: omega-3s fill a dietary gap that many people have, whereas coenzyme Q10 is more of a targeted supplement for specific clinical situations.

Another difference is the measurability of the effect. The action of omega-3s can be assessed by a lipid panel or the erythrocyte omega-3 index, whereas for Q10 routine tests are almost never used in ordinary practice.

Finally, dietary sources. Omega-3s are easy to obtain from mackerel, herring, salmon or sardines, whereas the amount of coenzyme Q10 in an ordinary diet is small even in meat and offal, so dietary correction here has limited scope.

Editorial conclusions

Omega-3s and coenzyme Q10 differ in everything: chemical nature, origin in the body, site of action and level of evidence. Essentially all they have in common is fat solubility and a “cardiac” reputation.

Omega-3 is a basic dietary supplement for those who do not eat enough oily fish, with a well-proven effect on triglycerides. Coenzyme Q10 is a narrowly specialised agent that makes sense primarily in older people, in heart failure or on a doctor's decision.

Taking one supplement does not make up for the absence of the other, but there is also no particular need to combine them “just to be safe” without a specific goal.

If you are interested in the practical choice between them, we recommend reading our article “Omega-3 vs Coenzyme Q10: what to choose and for whom”, as well as articles on the omega-3 index and on supplements while taking statins.

References

1. Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–2067.
2. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
3. Manson JE, Cook NR, Lee IM, et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.
4. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–649.
5. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20(6):591–598.
6. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34.
7. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981–1990.
8. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012;10(7):2815.